From the Toronto Star:
Pharmaceutical giants Sanofi-aventis of France and Bristol-Myers Squibb of the United States say Health Canada has given approval for the use of their blood-thinner Plavix to reduce the risk of heart attack, stroke or death in patients with all acute coronary syndromes.
The approval is an expanded indication for Plavix, which offers protection from all types of heart attacks.
"This new indication is an important advance in the treatment of ACS (acute coronary syndrome) for patients with STEMI (ST-segment elevation myocardial infarction) as myocardial infarction is a life-threatening condition," said Shamir Mehta, director of interventional cardiology at McMaster University and Hamilton Health Sciences. ...more
Tuesday, June 05, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment